Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19

This article was originally published here

The primary goal of this Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster. As many

The post Humanigen announces first patient dosed in phase 3 clinical study of lenzilumab in Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply